ACAD Description — Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system disorders. Co. has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist, targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.

Company Name: 
Acadia Pharmaceuticals Inc
Drugs & Pharmaceuticals
Number of ETFs Holding ACAD: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   ACAD Weight   ACAD Amount 
 VTI   0.01%   $67,878,717         
 XBI   0.88%   $57,817,449         
 VB   0.05%   $57,054,419         
 IWM   0.10%   $48,973,314         
 FBT   3.43%   $48,819,725         
 VBK   0.12%   $32,961,398         
 VXF   0.04%   $29,503,514         
 IWO   0.19%   $16,896,118         
 VHT   0.04%   $7,638,743         
 PBE   2.79%   $6,810,463         
List of all 32 ETFs holding ACAD »
Quotes delayed 20 minutes

Email EnvelopeFree ACAD Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Hold (2.44 out of 4)
2nd percentile
(ranked lower than approx. 98% of all stocks covered)

Analysts Forecast:
ACAD Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding ACAD | Acadia Pharmaceuticals Inc | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.